Alumis Reports Second Quarter 2025 Financial Results and Provides Corporate Update

–Completed enrollment in Phase 3 ONWARD clinical trials for envudeucitinib in moderate-to-severe plaque psoriasis; topline readout expected in early Q1 2026– –Completed enrollment in Phase 2b LUMUS clinical trial for envudeucitinib in systemic lupus erythematosus (SLE); topline readout expected in Q3 2026– –Completed merger with ACELYRIN, Inc. to strengthen financial position and support advancement of late-stage immunology pipeline– –Cash, cash equivalents and marketable securities of $486.3 million as of ...